Primary and Triage Cervical Screening Diagnostic Value of Methods for the Detection of Cervical Dysplasia

James Kinoti Njue, Margaret Muturi, Lucy Kamau, and Raphael Lwembe

1Department of Medical Laboratory Science, Kenyatta University, Kenya
2Department of Animal Science, Kenyatta University, Kenya
3Centre for Virus Research, Kenya Medical Research Institute (KEMRI), Kenya

Correspondence should be addressed to James Kinoti Njue; kinoti@hotmail.com

Received 15 June 2022; Revised 17 August 2022; Accepted 5 September 2022; Published 17 September 2022

Background. Cervical cancer is a leading cause of mortality among women globally. Approaches to reduce cervical cancer incidence and mortality are "screen-and-treat," where positive primary test only is used in the treatment and "screen, triage and treat," where treatment is based on positive primary and triage tests with/without histological analysis. Objectives. To determine cervical screening outcomes among HIV-infected and noninfected women using VIA, Pap smear, and HPV-PCR cervical screening methods and to determine the sensitivity, specificity, PPV and NPV of VIA, Pap smear, and HPV-PCR as primary test and sequential triage based on abnormal histopathology among HIV-infected and noninfected women. Methodology. This was a comparative cross-sectional study where women aged 18-46 years women underwent cervical screening and colposcopy-biopsy test as a positive-confirmatory test in the Referral Hospitals of Eastern Kenya. Results. A total of 317 (HIV negative: 156/317 (49.2%) and HIV positive: 161/317 (50.8%)) women were enrolled. Of these 81/317 (25.6%), 84/317 (26.5%), 96/317 (30.2%), and 78/122 (63.9%) participants had VIA, HPV DNA-PCR, Pap smear, and cervical histology positive results, respectively; average: 27.4% (HIV positive: 21.5%; HIV negative: 5.9%). Majority of women with LSIL [17/317 (5.4%)], HSIL [22/317 (6.9%)], invasive cancer [5/317 (1.6%)], cervicitis [45/317 (14.2%)], and candidiasis 47/317 (14.8%) were HIV-infected (p < 0.001). 78/317 (24.6%) participants had positive histology test [ASCUS: 34/317 (10.7%) CIN1:17/317 (5.3%), CIN2: 16/317 (5.0%), CIN3:6/317 (1.9%), and ICC: 5/317 (1.6%)] (p > 0.001). A higher primary diagnostic accuracy was established by HPV DNA-PCR (sensitivity: 95.5%; specificity: 92.6%) than Pap smear and VIA test while in triage testing, high sensitivity was obtained by HPV DNA-PCR parallel testing with VIA test (92.7%) and Pap smear test (92.7%) and VIA cotesting with Pap smear (99.9%). HIV-infected women had increased specificity and reduced sensitivity and diagnostic accuracy by both primary and triage testing approaches. Discussion. Abnormal cervical screening outcome was high among HIV-infected than noninfected women. HIV-infected women had significantly high cases of cervical neoplastic changes. The diagnostic value of primary tests increased upon concurrent testing with other test methods hence reducing the number of women who would have been referred for biopsy. Conclusion. High sensitivity and specificity in detection of CIN+ were established among HIV-infected than HIV noninfected women by HPV DNA-PCR and Pap smear than VIA test. HPV DNA-PCR test and Pap smear are more accurate in primary and sequential triage cervical screening based on abnormal histopathology outcomes among HIV-infected than noninfected women.

1. Background

Cancer of the cervix is the second type of cancer among women aged 15-44 years in Kenya [1, 2]. It is primarily caused by human papillomavirus (HPV), which can be sexually transmitted and causes cervical cells neoplastic changes leading to cervical cancer [2, 3]. Wide spectra of HPV types have been established through advances in genotyping technology and classified as "high-risk" or "low-risk" HPV based on their oncogenicity [1, 4–6]. HPV deoxyribonucleic acid (DNA) replicates in the basal cells of the cervix during the initial stages of infection and integrates into the host...
genome. HPV cervical infection may regress and clear or progress into cervical intraepithelial neoplasia (CIN) leading to intraepithelial cellular carcinoma (ICC).

The World Health Organization (WHO) approaches to reduce cervical cancer mortality are the "screen-and-treat" approach, where the decision to treat is based on a positive primary screening test only without triage (i.e. no second screening test and no histopathological diagnosis) and the "screen, triage and treat approach," where treatment is based on a positive primary and secondary screening test results with/without histologically confirmed diagnosis [7–10]. The WHO recommends HPV DNA detection as the primary screening test rather than visual Inspection or cytology preferably with triage in screening and treatment approaches among both the general population of women and women living with HIV [7]. Additionally, the WHO identifies research gaps and further considerations for more data on the specificity and sensitivity of cervical screening tests among women living with HIV and the impact of antiretroviral therapy (ART) on HPV-associated lesions to strengthen the screening recommendations [7].

Several visual inspections and cytologic and molecular methods are used in cervical screening to detect neoplastic cells. Visual inspection methods include less resource-intensive visual inspection with acetic acid or Lugol’s iodine (VIA/VILLI) test which provides prompt results and less cytotechnology, hence excellent for low-income settings. Here, the cervix with CIN lesions is whitened following acetic acid swabbing and visualized using naked eyes, magnifying camera, colposcope, or automated digital imaging. Cytologic methods include conventional Pap smear, liquid-based cytology, and dual staining in the identification of P16 and Ki-67 cancer markers. They are more resource-intensive methods and require a laboratory for slides-staining procedures by a cytologist, and reporting by a pathologist using the Bethesda 2001 guidelines [8] takes a longer turnaround time in some cases leading to a loss of patient follow-up. Molecular methods include high-risk HPV nucleic acid amplification tests (NAAT), DNA methylation, and protein biomarkers tests for HPV antibodies and oncoprotein. They are the most resource-intensive cervical screening methods that require a specialized laboratory and highly trained personnel to carry out DNA isolation with high-cost reagents and equipment. The cervical histology method is also a high resource-intensive gold-standard confirmatory method that requires a pathologist to read slides prepared from harvested cervical samples [7–11].

Literature reviews a wide range of diagnostic values in the detection of cervical dysplasia by studied population, applied methodology, and personnel. VIA screening method is associated with low specificity, while the Pap screening has reported higher specificity and sensitivity. HPV DNA-PCR method is associated with higher sensitivity, specificity, and

| Characteristics    | Category       | HIV serostatus [N (%)] | Total (N = 317) | p value |
|--------------------|----------------|------------------------|-----------------|---------|
|                    |                | HIV negative | HIV positive |             |         |
| Residence          | Embu           | 41 (12.9)  | 44 (13.9)  | 85 (26.8) | 0.359   |
|                    | Isiolo         | 38 (12.0)  | 26 (8.2)   | 64 (20.2) |         |
|                    | Kirinyaga      | 23 (7.3)   | 33 (10.4)  | 56 (17.7) |         |
|                    | Meru           | 40 (12.6)  | 41 (12.9)  | 81 (25.6) |         |
|                    | T. Nithi       | 14 (4.4)   | 17 (5.4)   | 31 (9.8)  |         |
| Age                | ≤35 years      | 69 (21.8)  | 93 (29.3)  | 162 (51.1) | 0.016** |
|                    | >35 years      | 87 (27.4)  | 68 (21.5)  | 155 (48.9) |         |
| Education level    | Primary        | 43 (13.6)  | 53 (16.7)  | 96 (30.3) | 0.216   |
|                    | Secondary      | 70 (22.1)  | 65 (20.5)  | 135 (42.6) |         |
|                    | College        | 37 (11.7)  | 30 (9.5)   | 67 (21.1) |         |
|                    | University     | 6 (1.9)    | 13 (4.1)   | 19 (6)    |         |
| Marital status     | Married        | 117 (36.9) | 109 (34.4) | 226 (71.3) | 0.416   |
|                    | Separated      | 14 (4.4)   | 18 (5.7)   | 32 (10.1) |         |
|                    | Single         | 19 (6)     | 22 (6.9)   | 41 (12.9) |         |
|                    | Divorced       | 6 (1.8)    | 12 (3.7)   | 18 (5.7)  |         |
| Income status§     | Low            | 106 (33.4) | 102 (32.2) | 208 (65.6) | 0.495   |
|                    | Middle         | 45 (14.5)  | 50 (15.8)  | 95 (30.0) |         |
|                    | High           | 5 (1.6)    | 9 (2.8)    | 14 (4.4)  |         |
| Total              | 156 (49.2)     | 161 (50.8) | 317 (100)  |         |

T. Nithi: Tharaka-Nithi County, §Income: low (1.90), middle (1.9-5.5), and high (>5.50) US$ PPP/day), **: the probability at the 0.05. Table 1 shows the total number of HIV-infected and noninfected women participants. It does not represent HIV prevalence in the region since most HIV-positive participants were recruited purposively from HIV Voluntary and Testing Centers (VCT) and Reproductive Health Clinics. This enabled in recruiting of a target population of HIV-infected participants.
positive predictive value (PPV) than other methods [8]. Since cervical cancer is preventable and has a longer precancerous stage, a time lasting a decade, the best and available diagnostic tools are required for early detection and management [10, 12, 13]. This precancerous stage is reduced among HIV-infected women who harbor a wide spectrum of HPV types with subsequently reduced infection clearance [5].

This study aimed to (1) determine cervical screening outcomes among HIV-infected and noninfected women using VIA, Pap smear, and HPV-PCR cervical screening methods and (2) determine the sensitivity, specificity, positive and negative predictive value, and diagnostic accuracy of VIA, Pap smear, and HPV-PCR as primary test and sequential triage based on abnormal histopathology among
Table 2: Cervical screening methods result from histology outcome of ASCUS and CIN+.

| Cervical screening methods and results | Result category | Categories of histological analysis (N = 78) | Positive (ASCUS, CIN+) | Negative | Total | P value |
|----------------------------------------|----------------|---------------------------------------------|------------------------|----------|-------|--------|
| **Primary screening approach**          |                |                                             |                        |          |       |        |
| Positive VIA test                       |                |                                             |                        |          |       |        |
| Normal                                 | FP             | ASCUS 24 (7.6)                              | 26 (8.2)               | 194 (61.2) | 220 (69.4) | 0.001* |
| Abnormal                                | TP             | ASCUS 10 (3.2)                              | 16 (5.0)               | 52 (16.4) | 97    |        |
| Positive HPV DNA-PCR                    |                |                                             |                        |          |       |        |
| Negative                                | FP             | ASCUS 23 (7.3)                              | 2 (0.6)                | 26 (8.2)  | 207 (65.3) | 0.001* |
| Abnormal                                | TP             | ASCUS 11 (3.5)                              | 16 (5.4)               | 52 (16.4) | 84    |        |
| Positive Pap smear test                 |                |                                             |                        |          |       |        |
| Normal                                 | FP             | ASCUS 22 (6.9)                              | 1 (0.3)                | 28 (8.8)  | 208 (65.6) | 0.001* |
| Abnormal                                | TP             | ASCUS 12 (3.8)                              | 15 (4.7)               | 50 (15.8) | 81    |        |
| **Triage screening approach with positive primary test** | | | | | | |
| Positive VIA test                       |                |                                             |                        |          |       |        |
| Pap smear                               | FP             | ASCUS 3 (0.9)                               | 1 (0.3)                | 4 (1.3)   | 3 (0.9) | 0.001* |
| Abnormal                                | TP             | ASCUS 9 (2.8)                               | 14 (4.4)               | 50 (15.8) | 50    |        |
| Positive HPV DNA-PCR                    |                |                                             |                        |          |       |        |
| VIA test                                | FP             | ASCUS 2 (0.6)                               | 3 (0.9)                | 8 (2.5)   | 13 (4.1) | 21 (6.6) | 0.001* |
| Positive                                | TP             | ASCUS 7 (2.2)                               | 12 (3.8)               | 43 (13.6) | 63    | 19 (9.9) |
| Abnormal Pap smear DNA-PCR              |                |                                             |                        |          |       |        |
| Negative                                | FP             | ASCUS 3 (0.9)                               | 1 (0.3)                | 5 (1.6)   | 21 (6.6) | 3 (0.9) | 0.001* |
| Positive                                | TP             | ASCUS 7 (2.2)                               | 14 (4.4)               | 47 (14.8) | 47    | 14 (8.1) |
| Total                                   |                | ASCUS 10 (3.2)                              | 16 (5.0)               | 52 (16.4) | 52    |        |
| Total                                   |                | ASCUS 34 (10.7)                             | 17 (5.3)               | 78 (24.6) | 137   | 0.001* |

VIA test: visual inspection with acetic acid test; HPV DNA-PCR: human papillomavirus deoxyribonucleic polymerase chain reaction; Abnormal histology: ASCUS: atypical squamous cells of unknown significant; CIN2+: cervical intraepithelial neoplasia; and ICC: intraepithelial cervical carcinoma; *: the probability at the 0.001 level; FP: false positive; TP: true positive. Table 2 shows the Primary cervical screening approach where results obtained by VIA, HPV-PCR, and Pap smear are categorized as positive, negative, normal, or abnormal by histology reports of ASCUS and CIN+ including ICC. In the triage screening approach, positive primary test results are combined with triage test results and categorized by histology report. Total positive results of ACSUS, CIN1, 2, 3, and ICC are also shown alongside negative samples and total (N = 317).
HIV-infected and noninfected women. These will assist in the development of effective screening strategies for early and accurate cervical abnormalities detection.

2. Methodology

We followed the methods described in our previous research publication [14] that focused on HPV types detected among HIV-infected and noninfected women in the same study region.

This was a comparative cross-sectional study carried out in Meru, Embu, Kirinyaga, Isiolo, and Chuka Referral Hospital’s Reproductive Health Clinics and HIV Voluntary Counseling and Testing (HIV-VCT) Centers from January 2018 to December 2019. Included were consenting women aged between 18 and 47 years. Excluded were menstruating, pregnant, and mentally incompetent women and those with an eroded cervix or a history of ablative procedures or medical treatment for cervical disease in the last six months [15].

2.1. Human Immunodeficiency Virus Determination. HIV serostatus was determined as per the national algorithm. Alere Determine® HIV-1/2 test (Abbott Laboratories, Abbott Park, IL) was used as a baseline screening test, First Table 3: Diagnostic value of cervical screening approaches in comparison with histology results.

| Cervical screening methods and approaches | Abnormal histology (%) | Sensitivity | Specificity | PPV | NPV | D/ A | Sensitivity | Specificity | PPV | NPV | D/ A | p value |
|------------------------------------------|------------------------|-------------|-------------|-----|-----|------|-------------|-------------|-----|-----|------|--------|
| **The primary cervical screening approach** |                        |             |             |     |     |      |             |             |     |     |      |        |
| VIA test                                 | 53.6                   | 81.2        | 53.6        | 81.2 | 77.6 | 95.5 | 79.9        | 43.3        | 99.1 | 82.0 | 0.001 |
| HPV DNA-PCR                              | 61.9                   | 86.6        | 61.9        | 86.6 | 81.7 | 93.2 | 84.2        | 48.8        | 98.7 | 85.5 | 0.001 |
| Pap smear                                | 61.7                   | 87.0        | 61.7        | 87.0 | 81.4 | 86.4 | 84.2        | 46.9        | 97.5 | 84.5 | 0.001 |
| **Triage cervical screening approach**    |                        |             |             |     |     |      |             |             |     |     |      |        |
| VIA and Pap smear                         | 92.0                   | 64.8        | 69.7        | 67.6 | 90.0 | 83.3 | 72.0        | 16.1        | 98.5 | 72.7 | 0.001 |
| HPV-PCR and VIA test                      | 84.3                   | 94.7        | 68.3        | 90.7 | 84.2 | 99.9 | 93.1        | 11.1        | 99.9 | 93.1 | 0.001 |
| Pap and HPV DNA-PCR                       | 90.4                   | 95.4        | 66.2        | 89.4 | 94.3 | 99.0 | 95.0        | 15.4        | 99.9 | 95.0 | 0.001 |

VIA: visual inspection with acetic acid test; HPV DNA-PCR: human papillomavirus deoxyribonucleic polymerase chain reaction; Abnormal histology: ASCUS: atypical squamous cells of unknown significance; CIN2+: cervical intraepithelial neoplasia (CIN2+); and ICC: intraepithelial cervical carcinoma; sensitivity = TP/(TP + FN); specificity = TN/(TN + FP); positive predictive value (PPV) = TP/(TP + FP); negative predictive value (NPV) = TN/(FN + TN); diagnostic accuracy = TP + TN/TP + TN + FP + FN, where TP = true positive; FP = false positive; TN = true negative; FN = false negative; p value: probability at the 0.001 level.

Table 4: Diagnostic value of cervical screening methods and approaches in comparison with histology results by HIV serostatus.

| Cervical screening approach and methods | HIV status | Diagnostic values of cervical screening methods | Sensitivity | Specificity | PPV | NPV | D/ A | p value |
|----------------------------------------|------------|-------------------------------------------------|-------------|-------------|-----|-----|------|--------|
| **The primary cervical screening approach** |            |                                                 |             |             |     |     |      |        |
| VIA                                    | Negative   | 75.0                                            | 91.2        | 31.6        | 98.5 | 92.5 | 0.001 |
|                                        | Positive   | 88.9                                            | 76.0        | 51.6        | 96.0 | 91.0 |        |
| Pap smear                              | Negative   | 87.5                                            | 91.2        | 35.0        | 99.3 | 93.5 | 0.001 |
|                                        | Positive   | 97.2                                            | 66.4        | 45.5        | 98.8 | 86.6 |        |
| HPV DNA-PCR                            | Negative   | 87.5                                            | 94.6        | 46.7        | 99.3 | 96.7 | 0.001 |
|                                        | Positive   | 97.2                                            | 72.8        | 50.7        | 98.9 | 91.5 |        |
| **Triage screening approach**           |            |                                                 |             |             |     |     |      |        |
| VIA test–Pap smear                      | Negative   | 75.0                                            | 95.3        | 46.2        | 98.6 | 96.4 | 0.001 |
|                                        | Positive   | 86.1                                            | 82.3        | 58.5        | 95.3 | 94.8 |        |
| Pap smear–HPV DNA-PCR                   | Negative   | 75.0                                            | 98.0        | 66.7        | 98.6 | 98.9 | 0.001 |
|                                        | Positive   | 94.4                                            | 80.0        | 57.6        | 98.0 | 96.1 |        |
| HPV DNA-PCR–VIA                        | Negative   | 62.5                                            | 95.9        | 45.5        | 97.9 | 96.0 | 0.001 |
|                                        | Positive   | 86.1                                            | 83.2        | 59.6        | 95.4 | 95.6 |        |

VIA: visual inspection with acetic acid test; HPV DNA-PCR: human papillomavirus deoxyribonucleic polymerase chain reaction; Abnormal histology: ASCUS: atypical squamous cells of unknown significant; CIN2+: cervical intraepithelial neoplasia (CIN2+); and ICC: intraepithelial cervical carcinoma; sensitivity = TP/(TP + FN); specificity = TN/(TN + FP); positive predictive value (PPV) = TP/(TP + FP); negative predictive value (NPV) = TN/(FN + TN); diagnostic accuracy = TP + TN/TP + TN + FP + FN, where TP = true positive; FP = false positive; TN = true negative; FN = false negative; p value: probability at the 0.001 level.
Response® HIV 1-2-0 card test (Premier Medical Corporation, Nani Daman, India) as a confirmatory test, while Uni-Gold™ Recombigen® HIV-1/2 (Trinity Biotech Jamestown, New York, US) was used as a tie-breaker test [13, 15].

2.2. Collection and Storage of Cervical Exfoliated Cell Samples. A disposable speculum was prewarmed in sterile warm distilled water and then lubricated before use. It was then used to examine the external genitalia and locate the cervical opening (OS) while the participant lays in a lithotomic position [7, 13, 16]. The mucus plug in OS was removed and wiped to ensure sufficient cells were collected. A cervical broom (Dacron cervical broom; Digene Corporation, Silver Spring, Maryland STM™) was softly rotated 360 degrees five times to exfoliate cells from the region of the transformation zone, squamocolumnar junction, and endocervical canal. Exfoliated cells were spread evenly and fixed immediately on a clean glass slide. The broom bristles were then dipped into Aqueous Minimum Essential Media (MEM), and the broom handle snapped so that it remained in the tightly closed vial stored at 1-4°C as described by the WHO guidelines [8, 17].

2.3. Visual Inspection by Acetic Acid Test. The cervix was smeared with a 3-5% acetic acid solution and observed under sufficient light after 30-60s for acetowhitenening around the cervical transformation zone. The test was reported as positive if acetowhitenening occurred and negative if there was no acetowhitenening [18, 19].

2.4. Cytology. A standardized protocol for Pap smear staining and examination was followed to detect cellular charges to the nuclei and cytoplasm following HPV infection. Cytopathologists supervised by a pathologist at Embu and Meru Hospitals were required to fill a pathology synoptic reporting form using the Bethesda 2001 guidelines for reporting Pap smear slides using a binocular microscope. Slides were later transferred to Kenya Medical Research Institute (KEMRI) for examination by a pathologist for results confirmation. Pap smear results were classified as normal or abnormal (ASCUS, CIN1, CIN2, CIN3, or ICC) [8].

2.5. Polymerase Chain Reaction Test. All samples underwent HPV DNA nested PCR by the following procedure:

2.5.1. DNA Extraction. Samples were subjected to the kit protocol to obtain DNA extracts by magnetic bead technique using a 96-well format HighPrep™ Viral-DNA/RNA, MagBio Genomics, Inc. USA/Canada Lysis kit and eluate stored at -20°C [7, 20, 21].

2.5.2. HPV Detection. This was achieved by amplifying an L1 portion of the HPV genome that is relatively conserved through L1 consensus nested PCR in the ABI-thermocycler Model 9600, Applied Biosystems® using HPV consensus primary primers PGMY09 (GCACAGGGACATAACAAATGG) and PGMY11 (CTGCTCCAAGGAAACTGATC) [15] that target the 450 bp region in the L1 ORF. Additional primer sets targeting the same region of L1, MGP5+(ACGTGGGATGT TTGTTACTGTGGTGATCTAC), and MGP6+(ACGT TGATGAAAAATACCTGATAATCATATTCCT) were used to produce shorter amplicon of ~160 bp in nested PCR [10, 15]. Positive control of CIN2+ and negative control of distillled water were incorporated in all primer cycles [21-23]. Working stock of 5μM PGMY09 primer (50 μL PGMY09 100 μM primer) and 5μM PGMY115μM (50 μL PGMY11 100 μM primer) were added to 350 μL and 750 μL molecular biology-grade water, respectively, and each filled to 1 mL total volume. They were later distributed each 5 μL working stock in 45–90 μL aliquots and stored at -20°C [8, 9].

In the primary PCR, 5 μL of the extracted DNA was amplified in a reaction mix containing 1× PCR buffer 2.0 mM MgCl2, 500 nM forward primer MY09, 500 nM reverse primer MY11, and 100 μM of each dNTPs and 0.13 units of Taq polymerase enzyme. In the nested PCR, 5 μL of the primary PCR product, 2.0 mM MgCl2, 500 nM of GP5+, 500 nM of GP6+, and 400 μM of dNTPs and 0.13 units of Taq polymerase enzyme were used. The cycling conditions were as follows: in primary PCR, initial denaturation at 95°C (4 minutes), the reaction was cycled 30 times at 95°C (20 seconds), 56°C (40 seconds), and 72°C (2 minutes) and then final extension at 72°C (7 minutes), and in nested PCR, initial denaturation at 95°C (4 minutes), cycling at 95°C (20 seconds), annealing at 60°C (40 seconds), extension at 72°C (7 seconds), and then final extension at 72°C (7 minutes) [8, 16].

2.5.3. Gel Electrophoresis and Visualization. The positive PCR products were purified using the QIAquick DNA purification kit™ Qiagen, Germany [21, 22]. 5 μl aliquot of the product was mixed with 1 μl of 6× loading dye and loaded onto a 2% agarose with 2 μl ethidium bromide gel alongside a 100 bp ladder for gel electrophoresis and ultraviolet visualization using 4% agarose-Tris-Borate-EDTA 10×. The presence of the expected 160 bp amplicon was considered positive for HPV DNA PCR [7].

2.6. Histology. All positive VIA, Pap smear, and HPV DNA-PCR participants underwent colposcopy and biopsy (as a Gold Standard method) [8]. If the result of the colposcopy was normal and satisfactory, it was considered negative, and in the case of abnormal or unsatisfactory colposcopy for the person, biopsy or endocervical curettage (ECC) was performed, and a sample was sent to the Pathology Department-KEMRI. If the report of pathology indicates...
an ASCUS, CIN lesion, or higher, it was considered a positive result. All biopsy samples alongside cytology reports were reviewed by a pathologist [21–23].

2.7. Statistical Analysis. Study results were analyzed using SPSS V16 software. Specificity, sensitivity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy are presented as percentages in primary and sequential triage by using confirmed abnormal histological analysis as gold standard. Cervical screening results by VIA, Pap smear and HPV-PCR cervical screening methods are presented as numbers and percentages. The level of significance was lower than 0.05.

2.8. Ethical Consideration. This study was approved by the KEMRI Scientific and Ethical Review Unit (approval number: KEMRI/SERU/CVR/004/3342). Participants were required to sign a consent here all steps and procedures for HIV and cervical exfoliated cell sample collection; analysis and collection of their results were explained.

3. Results

3.1. Table 1: Social Demographic Characteristics and HIV Serostatus of Participants. A total of 156/317 HIV-negative and 161/317 HIV-positive women were recruited. Most participants recruited into the study were residents from Embu County [85 (26.8%)], aged ≤35 years [219 (69.1%)], were educated up to secondary school level [135 (42.6%)] and married [226 (71.3%)], and those with low-income status earning less than $1.90 per day [208 (65.6%)]. Age was significantly associated (p = 0.016) with HIV status: more women aged below 35 years had a higher HIV infection rate than those aged over 35 years (Table 1).

3.2. Figure 1: Cervical Screening Results by HIV Status of Participants. Pap smear test produced most abnormal cytology results (96/317 (30.2%)) than other VIA tests (81/317 (25.6%)) and HPV-DNA-PCR (84/317 (26.5%)) which were established among HIV-infected than noninfected women (average: 27.4% (HIV infected: 21.5%; HIV non-infected: 5.9%)). Pap smear test reported high abnormal cervical screening outcomes by all methods and histology (78/122 (63.9%) cervical screening outcome. A significantly higher HPV infection, positive VI A test, abnormal cytology, and histology rate were established among HIV-infected than noninfected women (p < 0.001) (Figure 1).

3.3. Figure 2: Association between Pap Smear Cytological Analysis and Human Immunodeficiency Virus (HIV) Status. There was a significant association between abnormal cytology outcomes and HIV infection where the majority of women with LSIL [17/317 (5.4%)], HSIL [22/317 (6.9%)], invasive cancer [5/317 (1.6%)], cervicitis [45/317 (14.2%)], and candidiasis 47/317 (14.8%) were HIV-infected (p < 0.001) (Figure 2).

3.4. Table 2: Comparison of Cervical Screening Methods Results with Histology Outcome. Overall, 78/317 (24.6%) participants had positive histo logic tests which were significantly associated with other cervical diagnostic methods test outcomes. Several CIN1+ cases were reported as normal by VIA (CIN1: 1/78), HPV DNA-PCR (CIN2, 3 and ICC: 1/78), and Pap smear test (CIN1: 2/78, CIN3: 3/78, and CIN3: 1/78). However, the number of these cases was reduced upon triage testing by VIA-Pap smear test (CIN1: 1/78) and Pap smear-HPV DNA-PCR (CIN1: 2/78) (Table 2).

3.5. Table 3: Sensitivity, Specificity, Diagnostic Accuracy, and Positive and Negative Predictive Value of Cervical Screening Methods by Histology Outcome. HPV DNA-PCR had the highest sensitivity (61.9%), positive predictive value (61.9%), and diagnostic accuracy (81.7%), while Pap smear had the highest specificity value (87.0) in the primary testing approach. HPV DNA-PCR cotesting with Pap smear showed the highest specificity (95.4%), diagnostic accuracy (94.3%), and the highest negative predictive value when cotested with the VIA test (99.9%) in triage testing. All screening methods results were significantly associated with histological confirmation (p < 0.001) (Table 3).

There was reduced sensitivity and increased specificity among HIV-infected than noninfected women in the primary and triage cervical screening approach. There was no difference in NPV by primary or triage screening approach but the diagnostic accuracy increased by HIV-negativity status in all approaches (Table 4).

3.6. Figure 3. Agarose gel electrophoresis (2%) of PCR product. Lane T1: Size marker (500kb ladder); Lane T2: negative control; Lane T3: positive control; Lane T4 and T5: negative for HPV PCR product; Lane T6-T8: positive for HPV PCR product.

4. Discussion

This study used cervical histology outcomes to evaluate the diagnostic value of VIA, Pap smear, and HPV-PCR cervical screening methods in “screen-and-treat” and “screen, triage and treat” approaches among HIV-infected and noninfected women. This allows the findings to be pursued in a range of low- and middle-income settings with limited public health resources for early detection and treatment of cervical neoplasia.

On average, HIV-infected women had significantly high abnormal cervical screening outcomes by all methods and HIV status (average: 27.4% (HIV infected: 21.5%; HIV non-infected: 5.9%)). Pap smear test reported high abnormal cervical screening outcomes (30.2%) than other methods. A high HIV infection rate was also established by Pap smear outcome of Candida spp. and bacterial infection that is associated with cervical basal layer disruption allowing HPV and HIV entry [24, 25]. HIV infection has been detailed to favor HPV acquisition and persistence [4, 23]. This could be the reason for the higher HPV infection rate and varying degrees of cervical inflammation from mild to severe among HIV-infected women in this study and others [3, 23, 24]. Abnormal histology results are 63.1% (78/122); ASCUS and higher lesions (CIN1, CIN2, CIN3, and SCC and ICC) showed significant association (p < 0.001) with VIA test (25.6%), Pap smear (30.2%), and HPV DNA-PCR (26.5%) results. There is growing evidence regarding the impact of
ART among HIV-infected women on HPV-associated lesions [8] which calls for further studies.

The diagnostic value of primary test with VIA (true positive (TP): 16.4%; true negative (TN): 61.2%; false negative (FN): 14.2%; and false positive (FP): 8.2%) significantly reduced upon concurrently testing with Pap smear (TP: 14.5%; TN: 57.7%; FN: 6.3%; and FP: 14.5%) and HPV DNA-PCR. False-positive results that are incorrect outcomes of lesion-free women as CIN+ and FN results where CIN+ cases are not detected are a common occurrence in cervical screening [24]. Papillomavirus DNA-PCR primary testing produced negative results of ASCUS (7.3%) and in each category of CIN+ (0.3%) positive samples. However, CIN1, CIN2, CIN3, and ICC had 3.5%, 5.4%, 4.7% 1.6%, and 1.3% HPV true-positive tests, respectively. These values decreased upon triage test of HPV DNA-PCR with VIA (2.2%, 4.4%, 3.8%, and 1.6% for ASCUS, CIN1, CIN2, and CIN3, respectively). Failure to detect HPV in CIN+ samples occur in HPV false-negative case as seen in this study or when the cervical abnormality is misclassified and when the cervical abnormality is HPV-independent [24]. When Pap smear abnormal samples were subjected to HPV DNA-PCR test, the number of TP (15.8%) and TN (65.6%) reduced to 14.8% and 58.4%, respectively. Literature review triage testing produces minimal FP and FN than primary testing alone as established in this study. Therefore, primary results are applied in the “screen-and-treat approach”; greater populace benefits but the approach may lead to unnecessary treatment of negative cases or ignoring positive ones hence allowing widespread neoplastic changes to occur leading to cervical cancer as well as delay early detection [24–27].

In cervical screening, specificity, PPV, and diagnostic accuracy of a screening method are reflexes of FP outcome which can be a result of abnormal cervical cytology cases that spontaneously regress without progressing to cervical neoplasia upon biopsy [24]. In this study, the VIA test had the highest false-positive result [52/317 (16.4%)] than Pap smear [32 (10.1%)] and HPV DNA-PCR [31 (0.9%)] resulting in low sensitivity, specificity, and PPV (probability that a positive test is a true positive) and NPV (negative test is a true negative) as reported in other studies [24, 25]. VIA sensitivity, specificity, PPV, and diagnostic accuracy were notably high among HIV-infected than noninfected women.

Test sensitivity and negative predictive value increased when (1) a triage testing approach was applied instead of primary testing, (2) when HPV DNA-PCR was part of any triage, and (3) when applied for the detection of CIN+ without ASCUS. Sensitivity in the detection of ASCUS with CIN+ by VIA (53.6%), HPV-DNA-PCR (61.9%), and Pap cytology (61.7%) increased to 92% (VIA–Pap), 84.3% (HPV DNA-PCR–VIA), and 90.4% (Pap–HPV DNA-PCR) hence reducing the number of women who would have been referred for colposcopy in a resource-constrained setting. Specificity and PPV were high in (1) primary and triage cervical screening approach when confirmed with CIN+ without ASCUS and (2) among HIV-infected than noninfected women. The reason could be that there was a high number of true-positive cases when CIN+ samples were applied in confirmation unlike when ASCUS and CIN+ were combined. Latent and initial stages of HPV infection often have a low incidence of cervical neoplasia and a higher chance of false-negativity as the viral load is too low to be detected using HPV-PCR [28].

HIV-infected women showed reduced FP and FN and increased TN results than HIV noninfected in both primary and triage tests and hence increased specificity and sensitivity by all cervical screening methods. The reason could be HPV regression upon acquisition among HIV-infected women is low meaning that most infections will progress into cervical lesions and test positive by all cervical screening methods decreasing the number of false positives and increasing true positives.

This study, therefore, agrees with one of the seven prioritized WHO algorithms for HPV DNA detection in a screen, triage, and treat approach [7]. The use of this algorithm in this study significantly reduced the high number of HIV noninfected than HIV-infected women who would have undergone treatment if the primary screening approach alone was used.

The strength of this study was performing cervical screening on all participants using a primary and triage screening approach that led to accurate reporting and appropriate referral based on CIN+ histological outcomes, especially among HIV-infected women as recommended by WHO.

5. Conclusion

The clinical relevance of cervical screening is highly dependent on the sensitivity, specificity, positive and negative predictive, and diagnostic values of screening modalities. Pap smear tests produced more positive outcomes by HIV serostatus than other cervical screening methods. High sensitivity and specificity in detection of CIN+ were established among HIV-infected than HIV noninfected women by HPV DNA-PCR and Pap smear than VIA test. HPV DNA-PCR and Pap smear tests were also more accurate in primary and sequential triage cervical screening based on abnormal histopathology outcomes among HIV-infected than noninfected women. A high diagnostic value was obtained by all cervical screening methods when CIN+ histopathology outcome was used as a reference than CIN+ with ASCUS.

6. Recommendation

Values obtained and accuracy of results interpretation may differ with other studied populations and hence the need for expanded studies in other regions. More longitudinal data are needed on the effectiveness and cost-effectiveness of different cervical cancer screening strategies in cervical cancer reduction, especially among HIV-infected women.

Data Availability

The datasets are available from the corresponding author on reasonable request.
Additional Points

Access to Data. The datasets and questionnaires used in the study can be provided by the corresponding author upon request.

Disclosure

The funding institution had no role whatsoever in designing the study, sample and data analysis, or writing of the manuscript.

Conflicts of Interest

The authors declare that they have no conflict of interest.

Authors’ Contributions

NJK, MM, LK, and RL designed the study. NJK conducted the survey, analyzed and interpreted the data, and wrote the main manuscript text. All authors reviewed the final manuscript.

Acknowledgments

This study was supported by the Kenya National Council for Science Technology and Innovation (Ref: RCD/ST&I 6TH CALL PhD/086). We thank all staff of Level 5, Referral, and Teaching hospitals in Meru, Embu, Kirinyaga, Isiolo, and Tharaka-Nithi Counties of Eastern Kenya for enabling us to recruit their clients. Special thanks are due to the National Flu Laboratory and KEMRI HPV Laboratory for support in sample storage and analysis.

References

[1] L. Bruni, G. Albero, B. Serrano et al., ICO HPV Information Centre Human Papillomavirus and Related Diseases Report: World Summary Report, ICO/IARC Information Centre HPV Cancer, 2019.

[2] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: a Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394–424, 2018.

[3] M. Li, T. Liu, G. Luo et al., “Incidence, persistence, and clearance of cervical human papillomavirus among women in Guangdong, China 2007–2018: a retrospective cohort study,” Journal of Infection and Public Health, vol. 14, no. 1, pp. 42–49, 2021.

[4] D. Stelzle, L. F. Tanaka, K. K. Lee et al., “Estimates of the global burden of cervical cancer associated with HIV,” The Lancet Global Health, vol. 9, no. 2, pp. e161–e169, 2021.

[5] M. Akaaboune, B. Kenfack, M. Viviano et al., “Clearance and persistence of the human papillomavirus infection among Cameroonian women,” Women’s Health, vol. 14, article 174550651880564, 2018.

[6] J. Lei, A. Ploner, K. M. Elfström et al., “HPV vaccination and the risk of invasive cervical cancer,” New England Journal of Medicine, vol. 383, no. 14, pp. 1340–1348, 2020.

[7] World Health Organization, WHO Guidelines for Screening and Treatment of Cervical Pre-Cancer Lesions for Cervical Cancer Prevention, WHO, 2021.

[8] R. Jug and S. M. Bean, Bethesda Systemhttps://www.pathologyoutlines.com/topic/cervixcytologybethesda.html. 2021.

[9] World Health Organization, Guide to cancer early diagnosis, World Health Organization, 2017, https://apps.who.int/iris/handle/10665/254500. License: CC BY-NC-SA 3.0 IGO.

[10] E. Asha, D. Bansal, A. Acharya et al., “Human Papillomavirus (HPV) infection: molecular epidemiology, genotyping, seroprevalence, and associated risk factors among Arab women in Qatar,” PloS one, vol. 12, no. 1, article e0169197, 2017.

[11] A. Karagu, A. Ng’ang’a, J. Kibachio, and P. Gichangi, “Developing a National Cancer Control Plan through Effective Partnerships: A Case of Kenya National Cancer Control Strategy 2017-2022,” Journal of Global Oncology, vol. 4, Supplement 2, 2018.

[12] R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2020,” CA: a Cancer Journal for Clinicians, vol. 70, no. 1, pp. 7–30, 2020.

[13] K. Robert, M. Maryline, K. Jordan et al., “Factors influencing access of HIV and sexual and reproductive health services among adolescent key populations in Kenya,” International Journal of Public Health, vol. 65, no. 4, pp. 425–432, 2020.

[14] J. K. Njue, M. Muturi, L. Kamau, and R. Lwembe, “Human papillomavirus types associated with cervical dysplasia among HIV and non-HIV-infected women attending reproductive health clinics in eastern Kenya,” BioMed Research International, vol. 2021, Article ID 2250690, 10 pages, 2021.

[15] Ministry of Health, National Cancer Screening Guidelines, Ministry of Health, Kenya, National Cancer Screening Guidelines, 2019.

[16] E. Krug and C. Varghese, Guide for Establishing a Pathology Laboratory in the Context of Cancer Control, World Health Organization, Geneva, Switzerland, 2019.

[17] G. Kovacevic, V. Milosevic, N. Nikolic et al., “The prevalence of 30 HPV genotypes detected by EURORAH HPV in cervical samples among unvaccinated women from Vojvodina province, Serbia,” PLoS ONE, vol. 16, no. 4, article e0249134, 2021.

[18] Z. Pan, Y. Song, X. Zhe et al., “Screening for HPV infection in exfoliated cervical cells of women from different ethnic groups in Yili, Xinjiang, China,” Scientific Reports, vol. 9, no. 1, pp. 3468, 2019.

[19] X. Huang, C. Li, F. Li, J. Zhao, X. Wan, and K. Wang, “Cervicovaginal microbiota composition correlates with the acquisition of high-risk human papillomavirus types,” International Journal of Cancer, vol. 143, no. 3, pp. 621–634, 2018.

[20] T. Shibata and M. Nakagawa, “Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota,” bioRxiv, vol. 10, no. 1101, article 921619, 2020.

[21] H. Onywera, A. L. Williamson, Z. A. A. Mbula, D. Coetzee, and T. L. Meiring, “The cervical microbiota in reproductive-age South African women with and without human papillomavirus infection,” Papillomavirus Research, vol. 7, pp. 154–163, 2019.

[22] W. S. Chan, T. L. Chan, C. H. Au et al., “An economical nanopore sequencing assay for human papillomavirus (HPV) genotyping,” Diagnostic Pathology, vol. 15, no. 1, p. 45, 2020.
[23] S. Menon, A. Wusiman, M. C. Boily et al., “Epidemiology of HPV genotypes among HIV positive women in Kenya: a systematic review and meta-analysis,” *PLoS One*, vol. 11, no. 10, article e0163965, 2016.

[24] B. Xing, J. Guo, Y. Sheng, G. Wu, and Y. Zhao, “Human papillomavirus negative cervical cancer: a comprehensive review,” *Frontiers in Oncology*, vol. 10, article 606335, 2021.

[25] J. Han, E. Y. Ki, S. E. Rha, S. Y. Hur, and A. Lee, “Dedifferentiated endometrioid carcinoma of the uterus: report of four cases and review of literature,” *World Journal of Surgical Oncology*, vol. 15, no. 1, p. 17, 2017.

[26] F. I. Torres-Rojas, L. Alarcón-Romero, M. A. Leyva-Vázquez et al., “Methylation of the L1 gene and integration of human papillomavirus 16 and 18 in cervical carcinoma and premalignant lesions,” *Oncology Letters*, vol. 15, no. 2, pp. 2278–2286, 2017.

[27] M. Riibe, S. W. Sørbye, G. S. Simonsen, A. Sundsfjord, J. Ekgren, and J. M. Maltau, “Risk of cervical intraepithelial neoplasia grade 3 or higher (CIN3+) among women with HPV-test in 1990–1992, a 30-year follow-up study,” *Infectious Agents and Cancer*, vol. 16, no. 1, p. 46, 2021.

[28] P. T. Larsen, S. F. Jørgensen, M. Tranberg, and S. H. Njor, “Screening participation after a false-positive result in organized cervical cancer screening: a nationwide register-based cohort study,” *Scientific Reports Journal*, vol. 10, no. 1, 2020.